Document Detail


Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study.
MedLine Citation:
PMID:  21865355     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Type 2 amiodarone-induced thyrotoxicosis (AIT) is a destructive thyroiditis usually responsive to glucocorticoids. Whether continuation of amiodarone affects treatment outcome is unsettled.
OBJECTIVE: The objective of the study was to compare the outcome of glucocorticoid treatment in type 2 AIT patients who continued or withdrew amiodarone.
DESIGN: This was a matched retrospective cohort study.
SETTING: The study was conducted at a university center.
PATIENTS: Eighty-three consecutive patients with untreated type 2 AIT participated in the study. After matching with patients continuing amiodarone (AMIO-ON, n = 8), patients interrupting amiodarone were randomly selected in a 4:1 ratio (AMIO-OFF, n = 32).
INTERVENTION: All patients were treated with oral prednisone. Patients whose thyrotoxicosis recurred after glucocorticoid withdrawal were treated with a second course of prednisone.
MAIN OUTCOME MEASURE: Time and rate of cure were measured.
RESULTS: Median time to the first normalization of serum thyroid hormone levels did not significantly differ in AMIO-ON and AMIO-OFF patients (24 and 31 d, respectively; P = 0.326). Conversely, median time for stably restoring euthyroidism was 140 d in AMIO-ON patients and 47 d in AMIO-OFF patients (log rank, P = 0.011). In fact, AIT recurred in five of seven AMIO-ON patients (71.4%) and in only three of 32 AMIO-OFF patients (9.4%, P = 0.002), requiring readministration of prednisone. One AMIO-ON patient never reached thyroid hormone normalization during the study period. Factors associated with glucocorticoid failure were thyroid volume and amiodarone continuation.
CONCLUSIONS: Prednisone restores euthyroidism in most type 2 AIT patients, irrespective of amiodarone continuation or withdrawal. However, continuing amiodarone increases the recurrence rate of thyrotoxicosis, causing a delay in the stable restoration of euthyroidism and a longer exposure of the heart to thyroid hormone excess.
Authors:
Fausto Bogazzi; Luigi Bartalena; Luca Tomisti; Giuseppe Rossi; Sandra Brogioni; Enio Martino
Related Documents :
19713445 - Exhaled breath profiling enables discrimination of chronic obstructive pulmonary diseas...
12220475 - Evaluation of serum eosinophil cationic protein as a predictive marker for asthma exace...
9257365 - Aspergillus fumigatus asp fi dna is prevalent in sputum from patients with coal workers...
9721455 - Emergency cases of chronic obstructive pulmonary disease (copd) in adults and air pollu...
11153985 - Pure dislocation of the ankle: three case reports and literature review.
16569685 - Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary sj...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2011-08-24
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  96     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-07     Completed Date:  2011-12-23     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3374-80     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Amiodarone / adverse effects*
Anti-Arrhythmia Agents / adverse effects*
Cohort Studies
Female
Glucocorticoids / therapeutic use*
Humans
Male
Middle Aged
Pilot Projects
Prednisone / therapeutic use*
Retrospective Studies
Thyrotoxicosis / chemically induced*,  drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Glucocorticoids; N3RQ532IUT/Amiodarone; VB0R961HZT/Prednisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and...
Next Document:  Facing the Nuclear Threat: Thyroid Blocking Revisited.